

Bangladesh

Support for Vaccine: Measles Rubella

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Bangladesh						
2. Vaccine grant number:	19-BGD-34a-X, 19-BGD-35a-Y						
3. Date of Decision Letter:	26 June 2019						
4. Date of the Partnership Framework Agreement:	24 June 2013						
5. Programme title:	New Vaccine Support (NVS), Measles Rubella, Follow-up campaign						
6. Vaccine type:	Measles Rubella						
7. Requested product presentation and formulation of vaccine:	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration: ¹	2019						
9. Programme Budget (indicative): ²	(subject to the terms of the Partnership Framework Agreement)						
	n/a	2019	2020	2021	2022	2023	Total ²
Programme Budget (US\$)	n/a	10,749,000	-	-	-	-	10,749,000
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts: ³	(subject to the terms of the Partnership Framework Agreement)						
Type of supplies to be purchased with Gavi funds	n/a	2019					2020
Number of vaccine doses			16,509,900				-
Annual Amounts (US\$)	n/a	10,749,000					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	869,000	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	556,122	-	-	-	-
Total co-financing payments (US\$) (including freight)	566,000	-	-	-	-

16. Operational support for campaigns:

Year	Grant Number	Amount
2019	19-BGD-35a-Y	8,611,116

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020 N/A
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points.	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool.

To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign.	Within 3 months of end of campaign.																		
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign.	As soon as available.																		
<p>18. Financial clarifications: Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>																			
<p>19. Other conditions:</p> <ul style="list-style-type: none"> - Ministry of Health and Family Welfare of Bangladesh to confirm procurement agency/arrangements for related injection safety devices - Government of Bangladesh to share letter of commitment that expansion of the campaign age range will not jeopardise the target of 95% coverage for the Gavi-supported 9-59 month group; that the full cost of the additional vaccines and operational costs will be covered by Government (or other donor) resources; and that Gavi operational cost funds will not be used for the higher age range. - As available a copy of the revised Plan of Action and revised MNC&AH Operational Plan showing the allocation of resources to the campaign <p>As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.</p> <table border="1"> <thead> <tr> <th></th> <th>2019</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> </tr> </thead> <tbody> <tr> <td>Minimum number of doses to be financed from domestic resources</td> <td>2,599,441</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Minimum amount to be financed from domestic resources (US\$)</td> <td>1,663,642</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>			2019	2020	2021	2022	2023	Minimum number of doses to be financed from domestic resources	2,599,441	-	-	-	-	Minimum amount to be financed from domestic resources (US\$)	1,663,642	-	-	-	-
	2019	2020	2021	2022	2023														
Minimum number of doses to be financed from domestic resources	2,599,441	-	-	-	-														
Minimum amount to be financed from domestic resources (US\$)	1,663,642	-	-	-	-														

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 26 June 2019